BioPharma’s fiscal Q4 loss widens from year ago, revenues slip
Biopharmaceutical company BioPharma Inc. (Nasdaq:ARRY) after Monday’s close posted a net loss for its fiscal fourth quarter that widened from a year ago. Revenues also declined from the year-ago period due to lower collaboration revenue from the company’s internal drug discovery programs.
Shares lost 5.69%, or $0.50, to $8.29 out of the gate. For detailed price information and news stories on BioPharma, click ARRY.
